What percentage of patients with tardive dyskinesia reported their illness having a severe impact across their physical, psychological, and social lives? Take the quiz!
What percentage of patients with tardive dyskinesia reported their illness having a severe impact across their physical, psychological, and social lives? Take the quiz!
True or false: Long-term anticholinergic medication exposure can cause long-term consequences that surpass previously documented short-term cognitive effects.
True or false: Long-term anticholinergic medication exposure can cause long-term consequences that surpass previously documented short-term cognitive effects.
According to a recent study, what antibody levels were significantly higher in schizophrenia patients with tardive dyskinesia (TD)? Take the quiz to find out!
According to a recent study, what antibody levels were significantly higher in schizophrenia patients with tardive dyskinesia (TD)? Take the quiz to find out!
True or False: A notable percentage of psychiatrists said they would use an anticholinergic medication to manage symptoms of tardive dyskinesia in a patient.
True or False: A notable percentage of psychiatrists said they would use an anticholinergic medication to manage symptoms of tardive dyskinesia in a patient.
What percentage of participants in a recent post-hoc analysis of a long-term study saw improvement at weeks 24, 36, and 48 while taking once daily valbenazine? Take the quiz to find out.
What percentage of participants in a recent post-hoc analysis of a long-term study saw improvement at weeks 24, 36, and 48 while taking once daily valbenazine? Take the quiz to find out.
True or False: A notable percentage of psychiatrists said they would use an anticholinergic medication to manage symptoms of tardive dyskinesia in a patient.
True or False: A notable percentage of psychiatrists said they would use an anticholinergic medication to manage symptoms of tardive dyskinesia in a patient.
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
